400 Participants Needed

Diagnostic Stewardship for Ventilator-Associated Pneumonia

Recruiting at 2 trial locations
MN
SL
Overseen BySurbhi Leekha, MD
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Do I have to stop taking my current medications to join the trial?

The trial protocol does not specify whether you need to stop taking your current medications. However, it focuses on antibiotic use, so it's possible that changes to your antibiotic regimen might be discussed with your healthcare provider.

What data supports the idea that Diagnostic Stewardship for Ventilator-Associated Pneumonia is an effective treatment?

The available research does not provide specific data on Diagnostic Stewardship for Ventilator-Associated Pneumonia. However, it does show that similar interventions, like optimizing blood culture practices, can reduce unnecessary testing and improve the accuracy of results. For example, in one study, the rate of blood cultures ordered decreased significantly, and the positivity rate increased, indicating more accurate testing. This suggests that Diagnostic Stewardship could potentially improve outcomes by ensuring more precise and necessary testing.12345

What safety data is available for the treatment of Diagnostic Stewardship for Ventilator-Associated Pneumonia?

The provided research does not contain specific safety data for the treatment of Diagnostic Stewardship for Ventilator-Associated Pneumonia or its related interventions like Modified lab reporting. The studies focus on the use of voluntary incident reporting systems to improve patient safety in the ICU, but they do not provide direct safety data for the specific treatment in question.678910

Is the treatment in the trial 'Diagnostic Stewardship for Ventilator-Associated Pneumonia' a promising treatment?

Yes, the treatment is promising because it focuses on improving how doctors diagnose ventilator-associated pneumonia (VAP). This can help reduce unnecessary antibiotic use and ensure patients get the right care.1112131415

What is the purpose of this trial?

The goal of this pragmatic cluster-randomized crossover trial is to test if less unnecessary antibiotics are prescribed when the lab reports respiratory culture test results in a specific way for patients who have respiratory cultures obtained, but do not meet clinical criteria for ventilator associated pneumonia (VAP). The main question it aims to answer is: Does a modified culture reporting intervention reduce unnecessary antibiotics for ventilated patients in the intensive care unit (ICU)? Researchers will compare antibiotic use outcomes between eligible patients whose test results are communicated using the modified reporting and those with standard reporting of results.

Research Team

SL

Surbhi Leekha, MD

Principal Investigator

University of Maryland, Baltimore

Eligibility Criteria

This trial is for adults over 18 who are in the ICU, on a ventilator, and have had a respiratory culture taken more than 48 hours after admission. It's not for patients with severe immune system issues, recent transplants or certain therapies, ECMO at culture time, prisoners, or if the lab rejected their sample.

Inclusion Criteria

Patient located on ICU unit included in the study
You are using a machine to help you breathe.
You had a respiratory sample taken more than 48 hours after being admitted to the hospital.

Exclusion Criteria

I have not had a solid organ transplant or treatment for rejection in the last 6 months.
I had a stem cell transplant and am experiencing GVHD or taking 2 or more immunosuppressants.
I had a stem cell transplant or CAR-T therapy less than 6 months ago.
See 10 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Control Period

Laboratory reporting of respiratory cultures will continue per regular or routine laboratory protocols (standard reporting).

6 months

Intervention Period

The lab will publish a modified report for respiratory cultures which do not meet clinical criteria for pneumonia and have growth of organisms (other than normal respiratory flora).

6 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

28 days

Treatment Details

Interventions

  • Modified lab reporting
Trial Overview The study tests whether changing how labs report respiratory test results can reduce unnecessary antibiotic use in ICU patients on ventilators without clinical signs of pneumonia. Patients will be compared based on modified versus standard result reporting methods.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: InterventionExperimental Treatment1 Intervention
The lab will publish a modified report for respiratory cultures which do not meet clinical criteria for pneumonia and have growth of organisms (other than normal respiratory flora). The modified report will include the likelihood of colonization instead of reporting bacterial identification.
Group II: Control PeriodActive Control1 Intervention
Laboratory reporting of respiratory cultures will continue per regular or routine laboratory protocols (standard reporting).

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Maryland, Baltimore

Lead Sponsor

Trials
729
Recruited
540,000+

Centers for Disease Control and Prevention

Collaborator

Trials
902
Recruited
25,020,000+

George Washington University

Collaborator

Trials
263
Recruited
476,000+

Baylor College of Medicine

Collaborator

Trials
1,044
Recruited
6,031,000+

Virginia Commonwealth University

Collaborator

Trials
732
Recruited
22,900,000+

Findings from Research

A diagnostic stewardship program in a medical intensive care unit and five medicine units led to a significant reduction in blood culture (BCx) rates, from 27.7 to 22.8 BCx/100 patient-days in the MICU and from 10.9 to 7.7 BCx/100 patient-days in the combined medicine units, indicating improved optimization of BCx practices.
The program also resulted in an increase in BCx positivity in the MICU (from 8% to 11%) and a 21% decrease in solitary BCxs in the medicine units, demonstrating that clinician education and guidance can enhance the effectiveness of BCx without negatively impacting patient outcomes.
A Diagnostic Stewardship Intervention To Improve Blood Culture Use among Adult Nonneutropenic Inpatients: the DISTRIBUTE Study.Fabre, V., Klein, E., Salinas, AB., et al.[2021]
Laboratory testing plays a crucial role in patient outcomes, but its specific contributions are often difficult to quantify, highlighting the need for better measurement of its value in healthcare.
To enhance the effectiveness of laboratory medicine, it is essential to improve the use of biomarkers, establish standard protocols for evaluating clinical effectiveness, and foster collaboration between laboratory professionals and clinical staff, all aimed at optimizing patient care.
Improving clinical outcomes - towards patient-centred laboratory medicine.Hallworth, MJ.[2019]
Implementing MALDI-TOF mass spectrometry for rapid organism identification, along with pharmacy stewardship interventions, significantly reduced 30-day mortality in patients with bloodstream infections from 21% to 12%.
Despite the initial costs of MALDI-TOF equipment and dedicated pharmacist time, the total hospital costs per bloodstream infection decreased by $2,439, leading to an estimated annual savings of $2.34 million.
Cost Analysis of Implementing Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry Plus Real-Time Antimicrobial Stewardship Intervention for Bloodstream Infections.Patel, TS., Kaakeh, R., Nagel, JL., et al.[2022]

References

A Diagnostic Stewardship Intervention To Improve Blood Culture Use among Adult Nonneutropenic Inpatients: the DISTRIBUTE Study. [2021]
Improving clinical outcomes - towards patient-centred laboratory medicine. [2019]
Cost Analysis of Implementing Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry Plus Real-Time Antimicrobial Stewardship Intervention for Bloodstream Infections. [2022]
Evaluation of effectiveness of a computerized notification system for reporting critical values. [2022]
Fast multiplex bacterial PCR of bronchoalveolar lavage for antibiotic stewardship in hospitalised patients with pneumonia at risk of Gram-negative bacterial infection (Flagship II): a multicentre, randomised controlled trial. [2022]
Targeting errors in the ICU: use of a national database. [2018]
Integrating the intensive care unit safety reporting system with existing incident reporting systems. [2019]
Analyzing voluntary medical incident reports. [2016]
[Use of different patient safety reporting systems: much ado about nothing?]. [2014]
10.United Statespubmed.ncbi.nlm.nih.gov
Race Differences in Reported Harmful Patient Safety Events in Healthcare System High Reliability Organizations. [2021]
Understanding healthcare provider preferences for ordering respiratory cultures to diagnose ventilator associated pneumonia: A discrete choice experiment. [2022]
12.United Statespubmed.ncbi.nlm.nih.gov
Rapid and reproducible surveillance for ventilator-associated pneumonia. [2022]
13.United Statespubmed.ncbi.nlm.nih.gov
New diagnostic methods for pneumonia in the ICU. [2016]
14.United Statespubmed.ncbi.nlm.nih.gov
Healthcare providers consistently overestimate the diagnostic probability of ventilator-associated pneumonia. [2023]
15.United Statespubmed.ncbi.nlm.nih.gov
Ventilator-associated pneumonia: overdiagnosis and treatment are common in medical and surgical intensive care units. [2021]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security